{"title":"Authorities raise red flags about AstraZeneca’s vaccine press release [Updated]","link":"https://arstechnica.com/?p=1751492","date":1616529915000,"content":"<div id=\"rss-wrap\">\n<figure class=\"intro-image intro-left\"><img src=\"https://cdn.arstechnica.net/wp-content/uploads/2020/11/GettyImages-1229678428-800x527.jpg\" alt=\"Authorities raise red flags about AstraZeneca’s vaccine press release [Updated]\"><p class=\"caption\" style=\"font-size:0.8em\"><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2020/11/GettyImages-1229678428.jpg\" class=\"enlarge-link\" data-height=\"3072\" data-width=\"4660\">Enlarge</a> (credit: <a rel=\"nofollow\" class=\"caption-link\" href=\"https://www.gettyimages.com/detail/news-photo/vials-in-front-of-the-astrazeneca-british-biopharmaceutical-news-photo/1229678428?adppopup=true\">Getty| NurPhoto</a>)</p>  </figure><div><a name=\"page-1\"></a></div>\n<p><strong>Update 4 pm EDT</strong>: The board of experts monitoring the clinical trial of AstraZeneca’s COVID-19 vaccine determined that the vaccine is actually between 69 percent and 74 percent effective at preventing symptomatic disease—not 79 percent effective, as AstraZeneca announced Monday.</p>\n<p>According to <a href=\"https://www.washingtonpost.com/world/astrazeneca-oxford-vaccine-concerns/2021/03/23/2f931d34-8bc3-11eb-a33e-da28941cb9ac_story.html\">a report by The Washington Post</a>, the trial’s Data and Safety Monitoring Board (DSMB) had been in meetings with the company through February and March and saw data that indicated the 69-to-74 percent efficacy range. The board “strongly recommended” that the latest information be included in the company’s Monday press release.</p>\n<p>However, the press release Monday only stated an efficacy of 79 percent and, in a second press release Tuesday, the company noted that they had used a data cut-off of February 17.</p></div><p><a href=\"https://arstechnica.com/?p=1751492#p3\">Read 10 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1751492&comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"a56e85866f8224176e1e15b4d0df28bb51d1d487695eb7ea4f6f000b2ca5da20","category":"Tech"}